The data showed that the median overall survival for all patients with KRAS-mutant advanced lung cancer was 1.2 years, and the median overall survival ranged from 0.7 years (G13C) to 1.5 years (G12F) for specific KRAS point mutations, and no significant differences in survival were observed when comparing different KRAS point mutations [21]. Here, KRAS is linked to lung carcinoma.